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The influence of polygenic risk for bipolar disorder
on neural activation assessed using fMRI
HC Whalley1, M Papmeyer1, E Sprooten1, L Romaniuk1, DH Blackwood1, DC Glahn2, J Hall1, SM Lawrie1,
JE Sussmann1 and AM McIntosh1
Genome-wide association studies (GWAS) have demonstrated a significant polygenic contribution to bipolar disorder (BD)
where disease risk is determined by the summation of many alleles of small individual magnitude. Modelling polygenic risk
scores may be a powerful way of identifying disrupted brain regions whose genetic architecture is related to that of BD. We
determined the extent to which common genetic variation underlying risk to BD affected neural activation during an executive
processing/language task in individuals at familial risk of BD and healthy controls. Polygenic risk scores were calculated for
each individual based on GWAS data from the Psychiatric GWAS Consortium Bipolar Disorder Working Group (PGC-BD) of over
16 000 subjects. The familial group had a significantly higher polygene score than the control group (P¼ 0.04). There were no
significant group by polygene interaction effects in terms of association with brain activation. However, we did find that an
increasing polygenic risk allele load for BD was associated with increased activation in limbic regions previously implicated in
BD, including the anterior cingulate cortex and amygdala, across both groups. The findings suggest that this novel polygenic
approach to examine brain-imaging data may be a useful means of identifying genetically mediated traits mechanistically linked
to the aetiology of BD.
Translational Psychiatry (2012) 2, e130; doi:10.1038/tp.2012.60; published online 3 July 2012
Introduction
Evidence from family, twin and adoption studies has consis-
tently shown a significant genetic contribution to the aetiology
of bipolar disorder (BD) with heritability estimates of between
0.6 and 0.8.1,2 The identification of susceptibility genes for BD,
from both candidate gene and genome-wide association
studies (GWAS), means there are now a number of single-
nucleotide polymorphisms (SNPs) that are robustly associated
with risk of BD.2,3 Individually these variants account for a
small proportion of the heritability of BD, suggesting that each
risk allele may have a small additive and cumulative effect
across the genome. Evidence that liability to BD is due to the
accumulation of many common genetic variants is consistent
with the threshold-liability model of mental illness,4 and with
the observation that traits linked to BD are expressed to a
greater degree in unaffected family members than unrelated
individuals.5
In order to test the polygenic model of BD, two studies have
examined whether a polygenic risk score derived from a
discovery data set can be used to predict BD in an independent
target sample.6,7 Both studies concluded that the polygenic
contribution could explain a small but significant portion of the
total variation in liability, and both demonstrated that a
polygenic risk score could be used to classify cases signifi-
cantly better than chance in the target data set (maximumeffect
size: R2¼ 0.028, P¼ 1.7 109). This proportion of explained
variance is expected to increase with larger samples and with
more dense SNP genotyping arrays that capture a higher
proportion of total genetic variation.8
In order to better understand the genetic contributions to
BD, previous imaging studies have investigated the structural
and functional effects of individual SNPs in affected and
unaffected individuals, for example, CACNAIC, DISC1,
BDNF, DGKH and NRG1,9–13 or the interaction of a small
number of SNPs.14–17 Although these studies have been
informative regarding the effects of specific SNPs, a polygenic
model is likely to capture a greater proportion of the shared
genetic architecture of both the BD and imaging phenotypes.
It is therefore likely to identify brain regions linked to the
genetic aetiology of BD that have broader applicability than
the effects of individual alleles.
In the current study we generated a polygenic risk profile
score for BD based on all available Psychiatric GWAS
Consortium summary data for BD (https://pgc.unc.edu/). We
then sought to determine the impact of this score on brain
activation during performance of an executive function/
language task. This task has been shown to differentiate
patients with BD, and those at increased familial risk, from
healthy controls.18,19 Moreover, it probes neuropsychological
deficits in executive function, verbal initiation and verbal
fluency observed in patients with BD.20
Neuroimaging studies of BD patients have generally
implicated regions of the limbic network, including the
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amygdala and anterior cingulate cortex, and regions of the
prefrontal cortex.21 Functional imaging studies of BD have
reported hyperactivity of limbic regions, in line with theories
indicating a heightened emotional reactivity in the disorder.21–24
There is also evidence that unaffected relatives, who share
a proportion of genetic material with the affected patient,
display similar patterns of structural and functional abnorm-
ality to that seen in patients.25–34 Indeed, our previous study of
familial high-risk individuals versus controls demonstrated a
significant difference in amygdala activation between the groups
using the same task.19 Studies in relatives also allow the
investigation of genetic effects against a genetic and (shared)
environmental background similar to patients, but in the absence
of psychotropic medication and other illness-associated con-
founding factors. In the current studywehypothesised, based on
these previous findings, that the polygenic score derived for
BD would be associated with increased activation of fronto-
limbic circuitry underlying emotion regulation.
Methods and materials
Study population. The two groups examined in this study
comprised a group of individuals at familial risk of BD and
comparison group of healthy controls.19 We note that
individuals at familial risk of BD will also be at enhanced
risk for other affective disorders and the findings should be
viewed in this context. In brief, individuals at high genetic risk
of BDI (BDI) because of a close family history of the disorder
and control subjects were recruited as part of the Scottish
Bipolar Family Study as has been described in detail
elsewhere.19,35 To identify high-risk participants, caseloads
of psychiatrists across Scotland were searched for individuals
diagnosed with BDI. Diagnoses were confirmed with the
Structural Clinical Interview for DSM-IV-TR Axis I Disorders
(SCID-I)36 or the symptom checklist of the Operational
Criteria (OPCRIT).37 Subsequently, subjects affected by BD
were asked to identify a first or second-degree relative aged
16–25 years not suffering from the disorder. These
unaffected individuals were invited to participate in this
study providing that they had at least one first degree, or
two-second degree relatives suffering from BDI. Control
subjects with no personal history of BD or family history of
a mood disorder in first-degree relatives were identified from
the personal contacts of the bipolar high-risk subjects. Only
unrelated individuals were included in the current analysis.
Exclusion criteria for all groups included a personal history
of major depression, mania or hypomania, psychosis,
substance dependence, an IQ o70 or clinical diagnosis of
learning disability, or any major neurological disorder or
history of head injury that included loss of consciousness, and
any contraindications to MRI. A total of 87 bipolar high risk
and 71 controls provided genetic information, and a subgroup
comprising 73 bipolar high risk and 52 controls provided
suitable fMRI data. All participants provided written informed
consent and the study was approved by the multicentre
research ethics committee for Scotland.
Genotyping and derivation of polygenic scores. Genomic
DNA was extracted from venous blood. Genotyping was
conducted at the Wellcome Trust Clinical Research Facility,
Edinburgh, United Kingdom (www.wtcrf.ed.ac.uk) and used
the Illumina OmniExpress 730K SNP array (San Diego, CA,
USA). SNPs were excluded where the minor allele frequency
was o1%, if the call rate was o95% or if the w2-test for
Hardy–Weinberg Equilibrium was o1 103. Strand
ambiguous SNPs were also removed. The resulting SNP
set was then used to calculate multidimensional scaling
(MDS) components to assess for population stratification and
adjust for this in later analyses. The data were then imputed to
HapMap version 3 in mach software38 and then converted
back to plink (map/ped) format for later analysis.39
Summary results from the most recent international GWAS
of 7481 individuals with BD and 9250 controls was obtained
from PGC-BD. Details of the methods used by the consortium
are given elsewhere.7 Polygenic scores were calculated
according to the methods by Purcell et al.6 Four lists of
significant SNPs were generated from the PGC-BD associa-
tion data at significance thresholds of P¼ 0.5, P¼ 0.1,
P¼ 0.05 and P¼ 0.01. These were then used to select
common SNPs from our imaging-GWAS data sets resulting in
four separate files that contained the genotype of each
individual. Our primary analyses concerned those SNPs from
PGC-BD that met a significance level of P¼ 0.5 or less as this
was the level that most efficiently discriminated individuals
with and without BD in an independent test set.6 Full details of
findings for the other thresholds are presented in Supple-
mentary Information (Supplementary Table 2). In order to
identify polygenic effects due to independent SNPs in
linkage equilibrium with one another, each SNP set was
then pruned using a published method based on the
variance inflation factor.39 Linkage equilibrium-based SNP
pruning was conducted in a sliding window of 50 SNPs with
each calculation performed iteratively by moving the
window by five SNPs in the 30 direction. SNPs were
conservatively selected on the basis of a variance inflation
factor of 2 or less. Finally, these four SNP sets were then
scored using the sum of the number of reference alleles
multiplied by the natural logarithm of the odds ratio across
the whole genome.
All analyses were performed in Plink39 with the excep-
tion of imputation to HM3 and data manipulation,
which were performed in Mach (www.sph.umich.edu/csg/
abecasis/MACH) and R, respectively.38,40
Clinical assessments. All participants were interviewed by
one of two experienced psychiatrists (AMM, JES) using the
SCID36 to confirm the absence of any lifetime axis I disorders.
Current manic and depressive symptoms were rated using
the Young Mania Rating Scale41 and Hamilton Rating Scale
for Depression (HAM-D).42 Estimates of temperamental
variations in minor affective symptoms were assessed using
the Temperament Evaluation of Memphis, Pisa, Paris and
San Diego Autoquestionnaire (TEMPS-A),43 providing
measures of cyclothymic, depressive, hyperthymic, irritable
and anxious temperament. Statistical analysis of demographic
characteristics was conducted using independent t-tests
or w2-tests. For the clinical assessments and measures of
temperament, comparison of groups was conducted using
Mann–Whitney U-tests.
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Experimental paradigm. Subjects performed the verbal
initiation section of the Hayling Sentence Completion Test44
in the scanner.45 This is considered an extension of the
verbal fluency task, where constraint is based on sentence
context rather than letter or semantic category. Briefly,
subjects were shown sentences with the last word missing
and asked to silently think of an appropriate word to complete
the sentence and press a button when they had done so. The
task has four levels of difficulty, according to the range of
suitable completion words suggested by the sentence
context. This design allows a standard subtraction analysis
(sentence completion versus baseline) and a parametric
analysis (examining areas of increasing activation with
increasing task difficulty). Sentences were presented in
blocks of fixed difficulty. Each block lasted 40 s and
included eight sentences. Sentences were presented for a
period of 3 s followed by a fixation cross for 2 s. The baseline
condition consisted of viewing a screen of white circles on a
black background for 40 s. The order of the blocks was
pseudo-random, and each block was repeated four times
using different sentences.
Immediately after scanning, subjects were given the same
sequence of sentences on paper and requested to complete
each sentence with the word they first thought of in the
scanner. ‘Word appropriateness’ scores were determined
from the word frequency list of sentence completion norms.46
A score of one was given to the most frequently produced
word in theword frequency list, a score of two for the nextmost
frequently produced word and so on.
Scanning procedure. Imaging was carried out at the Brain
Imaging Research Centre (BIRC) for Scotland on a GE 1.5T
Signa scanner (GE Medical, Milwaukee, WI, USA). The
functional imaging protocol consisted of axial gradient-echo
planar images (EPI) (TR/TE¼ 2000/40ms; matrix ¼ 64 64;
field of view (fov)¼ 24cm) acquired continually during the
experimental paradigm. Twenty-seven contiguous 5mm
slices were acquired within each TR. Each EPI acquisition
was run for 404 volumes the first four of which were discarded.
The T1 sequence yielded 180 contiguous 1.2mm coronal
slices (matrix¼ 192 192; fov¼ 24cm; flip angle¼ 81). Visual
stimuli were presented using a screen (IFIS, MRI Devices,
Waukesha, WI, USA) placed in the bore of the magnet.
Image processing and analysis. The EPI and T1 images
were reconstructed into nifti format (Mayo Foundation,
Rochester, MN, USA) using DICOM convert functions
available in SPM5 (Statistical Parametric Mapping: The
Wellcome Department of Cognitive Neurology and
collaborators, Institute of Neurology, London) running in
Matlab (The MathWorks, Natick, MA, USA). Images were
pre-processed using standard protocols available in SPM5.
All EPI images were realigned to the mean volume in the
series. Functional images were then normalised according to
standard co-registration procedures using the individual’s
structural scan. Finally, all realigned and normalised images
were smoothed with an 8 8 8mm3 full width half
maximum (FWHM) Gaussian filter.
First-level statistical analysis was performed using the
general linear model approach. At the individual subject level
the data were modelled with four conditions corresponding to
the four difficulty levels each modelled by a boxcar convolved
with a synthetic haemodynamic response function. Estimates
of the subject’s movement during the scan were entered as
‘covariates of no interest’. Before fitting the model, the
participant’s data was filtered in the time domain using high
pass filter (128 s cutoff) and serial correlations were
accounted for by using the first order autoregressive model.
Contrasts were constructed to examine all four levels of
sentence completion difficulty versus baseline, and areas of
increasing activation with increasing task difficulty (the
parametric contrast).
Second-level analysis. For each contrast of interest
(sentence completion versus baseline and parametric
effects), one contrast image per subject was entered into a
second-level random effects analysis. The polygene score for
each individual was entered into a full factorial model as a
single regressor per group, hence adjusting for any main group
effects. As described above the three MDS factors were
entered as additional ‘nuisance’ covariates in the analysis
to control for population stratification. Contrasts were then
constructed to examine polygene  group-interaction effects.
Positive and negative associations across the groups between
the polygene score and activation were then explored.
Statistical maps were thresholded at a level of Po0.001
(uncorrected) and regions were considered significant at a
cluster level of Po0.05, corrected for multiple comparisons.
All coordinates are quoted in Montreal Neurological Institute
(MNI) convention (http://www.mni.mcgill.ca) and images are
overlaid onto standard brain in MNI space using Mango
software package (http://ric.uthscsa.edu/mango). On the
basis of our prior hypothesis, small volume corrections
were applied for the amygdala created using the WFU
PickAtlas47,48 as in our previous study.19
Results
Demographic, clinical, temperament and behavioural
measures. Subject details are presented in Table 1.
There were no significant differences between the groups in
terms of age, gender, handedness or NART IQ. The
groups differed in terms of the polygenic score for BD, with
the familial group scoring significantly higher than controls
(P¼ 0.04). For the clinical and temperament measures, the
groups differed on measures of depression (as determined by
the HAM-D, P¼ 0.03), and cyclothymic temperament
(P¼ 0.03), with the high-risk group scoring highest for both
measures as reported previously in this sample.19 The
polygene score did not correlate with NART IQ, or any of
the clinical measures as described above, for the groups
combined, or analysed separately. There were no significant
differences in the within-scanner measures of reaction time or
post-scan word appropriateness scores between the groups
for those who underwent fMRI (demographics for these
individuals are supplied as Supplementary Material). These
measures also did not correlate with the polygene score, for
the groups combined, or analysed separately. Both groups
demonstrated the typical gradation in these behavioural
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measures according to task difficulty demonstrating
compliance with the task.19
Task-related brain activation patterns. The controls
demonstrated the expected patterns of brain activation and
behavioural responses indicating subjects were performing
the task appropriately in the scanner.19,45,49 Regions
activated for the sentence completion versus baseline
contrast included the left medial and lateral prefrontal
regions, left lateral temporal cortex, sub-cortical structures,
left lateral parietal cortex, occipital lobes bilaterally and
right cerebellum (see Supplementary Figure 1). Regions
where there was reduced activation during the task (baseline
greater than sentence completion) included the anterior
cingulate cortex and amygdala. For the parametric contrast,
all groups demonstrated activation in similar areas
including left lateral and medial prefrontal cortex, left lateral
temporal cortex and right cerebellum. The main patterns of
activation and main group differences have been presented
previously.19
Polygenic score and brain activation
Sentence completion versus baseline. For the sentence
completion versus baseline contrast, there were no
statistically significant polygene  group-interaction
effects. There was, however, a significant positive
association between the polygene score and activation in
the anterior cingulate cortex (Po0.001, KE ¼ 477, Z¼ 4.30,
x¼ 2, y¼ 40, z¼6, r¼ 0.32 corrected for multiple
comparisons at the whole brain level,) and in the right
amygdala (P¼ 0.02, KE¼ 40, Z¼ 3.39, x¼ 18, y¼6,
z¼14, r¼ 0.30 applying small volume correction for the
amygdala) across the groups (see Figures 1 and 2). These
polygenic effects were present over and above any main
group effects, as group was taken into account in the
statistical model. There were no regions of significant
negative associations with the genetic score.
Parametric contrast. For the parametric contrast, there were
no significant positive or negative associations between
activation and polygene score across the groups and no
evidence for interaction effects between the groups.
Group effects controlling for polygene score. Based on our
previous results demonstrating increased amygdala
activation in the bipolar high-risk individuals versus
controls, we further explored the data to determine whether
there was any attenuation of the previously significant group
differences. We found that although there were differences in
amygdala activation occurring in the same direction as we
reported in the previous paper,19 these effects were
attenuated and no longer statistically significant for either
the sentence completion versus baseline, or for the
parametric contrast. These results demonstrate that
differences in polygenic load may have mediated our
previous finding of increased amygdala activation in the
high-risk group.
Population stratification. We also examined the relationship
between the MDS components included in the model
addressing population stratification and the extracted
values from the clusters of activation associated with the
polygene score, as above (the sgACC and amygdala). There
were no significant correlations between these measures
indicating that the above findings were not confounded by
population stratification.
Table 1 Participants details
Controls (n¼ 71) Bipolar high risk (n¼ 87) t/Z P
Demographics
Mean age (years) (s.d.) 20.66 (2.40) 20.89 (2.88) 0.52 0.60
Gender (M:F) 36:35 — 43:44 — 0.03a 0.87
Handedness (R:L+mixed) 66:5 — 79:8 — 0.24a 0.62
Mean NART IQ (s.d.) 109.19 (7.42) 108.41 (9.00) 0.58 0.56
Polygene score
Polygene score 0.2290 (0.05) 0.2466 (0.06) 2.05 0.04
Clinical measuresb (median (interquartile range))
Young Mania Rating Scale score 0 (0) 0 (0) 1.05 0.30
Hamilton Depression Scale score 0 (1) 0 (2) 2.19 0.03
Temperament measuresb
TEMPS-A (median (interquartile range))
Cyclothymia 1 (3.5) 2 (3.5) 2.17 0.03
Depressive 0 (2) 0 (1) 0.06 0.95
Irritability 1 (2) 1 (2.5) 1.57 1.16
Hyperthymia 3 (3) 2 (3) 0.84 0.40
Anxious 1 (1.5) 0 (2) 0.55 0.58
Total score 7 (9) 8 (9) 0.77 0.44
Behavioural measures
Word appropriateness scores 3.04 (0.54) 2.91 (0.54) 1.38 0.17
Reaction time 2473 (619) 2558 (631) 0.75 0.46
aw2-test. bMann–Whitney tests, median and interquartile range presented for skewed variables. Task-related behavioural measures only for those who underwent
imaging protocol (n¼ 52, n¼ 73 for controls and high risk, respectively).
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Discussion
In the current study we derived an overall polygenic risk profile
score for BD in those at familial risk and healthy controls, and
examined the collective impact of these risk variants on brain
Figure 2 Scatter graphs of associations between the polygene score and
activation in significant clusters. Depicts graphs of extracted data for clusters of
significant association in (a) anterior cingulate and (b) amygdala. Triangles
represent control subjects, cross hairs represent bipolar high-risk individuals. There
were no significant groups  polygene score interaction effects. Overall Pearson’s
r-values were r¼ 0.32 for the sgACC and r¼ 0.30 for amygdala. For the groups
separately, controls r¼ 0.50, r¼ 0.45, and for bipolar high-risk r¼ 0.20, r¼ 0.18
for the sgACC and amygdala, respectively.
Figure 1 Associations between polygene score and activation. Depicts regions
of increasing activation with increasing polygenic score for BD (a) in subgenual
anterior cingulate and (b) amygdala. Images are overlaid onto standard brain in MNI
space using Mango software package (http://ric.uthscsa.edu/mango). Map
represents F-statistic images thresholded equivalent to P uncorrected¼ 0.001,
see methods for further details.
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activation. We report a significant difference in polygene
scores between the groups, where the familial group demon-
strated higher profile scores for BD than controls. We did not
find any evidence for interaction effects between polygene
score and group, but we did demonstrate a significant positive
association between an increasing risk score for BD and
activation in the subgenual portion of the anterior cingulate
cortex (sgACC, BA 32), and in the amygdala. Importantly, we
were able to show these effects of overall risk on brain
activation in the absence of confounding disease and
medication effects. There was also no evidence for significant
relationships between activation in these clusters and the
MDS components indicating that these results were not
significantly influenced by population stratification effects.
Neuroimaging and neuropathological studies have consis-
tently implicated the sgACC in mood disorders, including
BD.21,24,50–52 Neuroimaging studies indicate differences in
the activation patterns of the ACC in both early and later
stages of the illness, and in those at familial risk.53,54
Functional imaging studies in healthy controls have sug-
gested that this region is involved in the regulation of
emotional behaviour,50 and activation in this region has also
been demonstrated to be associated with severity of
depressive symptoms55 and with sadness.56 The sgACC
has strong anatomical connections to the amygdala, which is
similarly implicated in the pathophysiology of BD.22,23,57,58
The amygdala has an important role in emotional processing
and in the attribution of emotion and motivational salience
to stimuli. Amygdala dysfunction has been found in BD
irrespective of mood state, in adulthood and adolescence,
and in those at familial risk.23,59 Both of these regions have
also been previously implicated in imaging studies of
individual genetic loci associated with risk to the disorder,
such as CACNA1C.60,61
The sgACC and amygdala form part of a network
traditionally implicated in neurobiological models of BD.
Thesemodels suggest that in BD there is increased emotional
reactivity along with an imbalance in the neural systems
responsible for regulating emotional states.22,23,62,63 Regions
of the ventral-limbic pathway, which includes the ACC and
amygdala, are specifically proposed to be involved in the
ability to identify the emotional significance of stimuli, the
production of affective states and regulation of emotional
responses. The complimentary dorsal system involving the
prefrontal cortex is proposed to sub-serve more cognitive
aspects of the regulation of affective states.22,23 It is
suggested therefore that abnormalities in these functional
systems controlling emotional reactivity might underlie deficits
in emotional regulation and predispose individuals to devel-
opment of the disease. The current findings are therefore
highly consistent with both the literature and neurobiological
models of the disorder and indicate an effect of cumulative
genetic risk on these regions.
In our previous imaging study we reported that the bipolar
high-risk cohort failed to show normal inhibition of the
amygdala in response to increasing cognitive load.19 The
sgACC was also found to demonstrate task-related deactiva-
tion (see Supplementary Figure 1). The current findings
therefore suggest that there is a failure to demonstrate normal
inhibition of these regions in the context of a cognitive task,
which relates to the degree of genetic risk for BD. A failure to
inhibit activation of these limbic regions may therefore
represent a heritable feature of the disorder and may underlie
the abnormally sensitized response to non-emotional stimuli
seen in the disorder. As we had previously reported a
significant difference in amygdala activation between the
groups,19 we further explored the data to determine whether
this difference would still be present if the polygene score was
controlled for in the statistical model. We report that the group
difference in the amygdala was no longer significant,
strengthening the suggestion that there is an important
contribution of polygenetic effects to amygdala activation in
this context.
The polygenetic score for BD was significantly higher in our
familial BD group than in the control sample, supporting the
liability threshold model for BD. It should be considered,
however, that because of the age of the individuals in the
current study, the familial group will likely contain individuals
who will remain well, along with individuals who will go on to
develop psychiatric illness. We could speculate that high-risk
individuals who subsequently become unwell may carry an
increased number of risk alleles, whereas those who remain
well carry protective alleles. Further longitudinal clinical
investigation of these individuals will allow determination of
these issues. Another important finding is that the polygene
score was associated with activation in these ventral-limbic
regions across both study groups with no evidence of
significant interaction effects. The current findings suggest
therefore that polygenic risk load exerts an effect on neural
activation independent of group status. This indeed may have
been anticipated as the polygene score is considered to
capture a sizable proportion of variation in genetic liability.6
This is also what might be expected under an additive model,
as the control participants in our sample also carried a variable
number of risk-alleles. On studying effects of individual SNPs,
we previously reported significant gene by group-interaction
effects in individuals at familial risk and controls.13 This we
interpreted as relating to the presence of an existing genetic
background in the familial sample, consistent with the current
findings.
In terms of future directions, polygenic risk profiling will
enable further studies of psychiatric disorder and their shared
genetic architecture with measures of brain structure and
function, leading ultimately to the identification of shared
variants and biological pathways. Using polygenetic risk
profiling, it may also be possible to subsequently model
complex psychiatric disorders in vitro, selecting individuals
from the extremes of the distribution in order to identify the
cellular process that underlie the imaging findings and disease
biology.
The main limitations of the current study relate to sample
size, which although substantial in terms of functional
imaging, is relatively small in terms of genetic studies. Also,
owing to the diversity of functional imaging paradigms applied
across the field and due to practicalities in recruiting such a
large familial sample, wewere not able to perform a replication
analysis of these findings. The findings should therefore be
viewed considering these limitations.
In conclusion, we demonstrate that activation in regions
known to be involved in the regulation of mood, and implicated
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in theoretical models of BD, are associatedwith overall genetic
risk for the illness. These results suggest that hyper-activation
in these regions may indeed be a trait-related feature of the
disorder with an overlapping genetic architecture with BD. The
advantage of this approach is that the polygenic score takes
account of cumulative risk from multiple weakly associated
genomic loci, and examines their overall association with
neuroimaging measures, which to our knowledge have not
previously been explored in BD. Previously, genetic models
based on family studies would have determined risk to the
disorder based on proximal distance to the primary affected
family member hence all first-degree relatives would be
assumed to have the same genetic risk. In the current study,
however, polygenetic risk scores vary depending on each
individual’s profile of contributing risk alleles and this may
therefore capture more of the phenotypic variation due to
genetic factors than other approaches. The current findings
therefore contribute to the understanding of deficits seen in
patient groups by suggesting a mechanistic link between trait
features of the disorder and genetic aetiology.
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